ABELTINO, Manuela
 Distribuzione geografica
Continente #
EU - Europa 705
NA - Nord America 566
AS - Asia 397
AF - Africa 20
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.689
Nazione #
US - Stati Uniti d'America 550
CN - Cina 234
IT - Italia 184
SE - Svezia 165
FI - Finlandia 104
IE - Irlanda 99
SG - Singapore 79
DE - Germania 69
TR - Turchia 49
UA - Ucraina 22
CI - Costa d'Avorio 19
JP - Giappone 18
CA - Canada 16
RO - Romania 16
BE - Belgio 14
AT - Austria 10
VN - Vietnam 8
IN - India 7
CZ - Repubblica Ceca 6
GB - Regno Unito 4
BG - Bulgaria 2
CH - Svizzera 2
DK - Danimarca 2
ES - Italia 2
FR - Francia 2
NL - Olanda 2
CM - Camerun 1
EU - Europa 1
IR - Iran 1
PK - Pakistan 1
Totale 1.689
Città #
Dublin 99
Chandler 91
Ann Arbor 85
Singapore 62
Jacksonville 54
Parma 50
Izmir 41
Nanjing 41
Ashburn 39
Beijing 36
Dearborn 31
Boardman 28
Munich 23
San Mateo 21
Shanghai 20
Abidjan 19
Bologna 18
Tokyo 18
Focsani 16
Princeton 16
Toronto 16
Nanchang 15
Shenyang 15
Brussels 14
Falls Church 14
Kunming 14
Jinan 13
Des Moines 10
Wilmington 10
Helsinki 9
Vienna 9
Bremen 8
Dong Ket 8
Hebei 8
Jiaxing 8
Kocaeli 8
New York 8
Düsseldorf 7
Hangzhou 7
Milan 7
Arzano 6
Changsha 6
Hefei 6
Piacenza 6
Redmond 6
Cambridge 5
Santa Clara 5
Taizhou 5
Verona 5
Langhirano 4
Novara 4
Reggio Emilia 4
Savignano Sul Rubicone 4
Seattle 4
Tianjin 4
Woodbridge 4
Brno 3
Chengdu 3
Frankfurt am Main 3
Los Angeles 3
Modena 3
Mountain View 3
Reggio Nell'emilia 3
Zhengzhou 3
Amsterdam 2
Cremona 2
Frederiksberg 2
Fremont 2
Fuzhou 2
Gurgaon 2
Guwahati 2
Inzago 2
Leawood 2
Lumezzane 2
Madrid 2
Marghera 2
Marseille 2
Mestre 2
Olomouc 2
Orange 2
Padova 2
Perugia 2
Pune 2
Redwood City 2
Rockville 2
Sala Baganza 2
Treviso 2
Walnut 2
Abbiategrasso 1
Ahmedabad 1
Ardabil 1
Bari 1
Bioggio 1
Böblingen 1
Chongqing 1
Clifton 1
Council Bluffs 1
Dallas 1
Fidenza 1
Guangzhou 1
Totale 1.178
Nome #
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma 203
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH+-LEUKEMIA 129
The Pharmacological Blockade of Phosphodiesterase IV Potentiates the Anti-Tumor Effects of Arsenic Trioxide (ATO) in Acute Myelogenous Leukemia Cells through Multiple Signaling Pathways 127
Are the Myeloma bone microevironment cells tumoral or not? 110
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 99
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 98
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 94
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 91
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 89
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 89
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 80
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 78
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 76
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 73
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 71
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 69
MEK1/2 KINASES DISABLE THE TUMOR SUPPRESSOR FUNCTIONS OF NATIVE BCR AND ABL1 KINASES TO IMPAIR ANTICANCER DRUGS’ RESPONSIVENESS IN TKI-RESISTANT PHILADELPHIA POSITIVE LEUKEMIAS 60
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia 55
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH plus -LEUKEMIA 37
Totale 1.728
Categoria #
all - tutte 6.269
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.269


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020198 0 0 0 0 19 33 37 12 23 36 16 22
2020/2021197 1 16 5 1 47 16 3 8 48 15 21 16
2021/2022179 5 8 4 31 9 10 20 18 9 11 25 29
2022/2023402 56 53 35 26 46 29 14 9 110 5 15 4
2023/2024220 17 13 13 7 24 38 19 9 7 15 10 48
2024/2025190 51 31 24 49 35 0 0 0 0 0 0 0
Totale 1.728